chrisvoncsefalvay/vaers-outcomes huggingface dataset:
First vaccine, no major symptoms (04/09/2021) besides sore arm and flush feeling for ~1 hour around 7 hours after vaccine issued.   Second vaccine (04/29/2021), slight headache after about 6 hours?woke up at 2:30am (11 hours after second vaccine) with flush feeling/light sweating but no fever. Triggered my vasovagal syncope (had this happen with other vaccines before so no big deal) to have a heavier heartbeat (about 10-20bpm higher than normal) for about 2 hours. Insomnia until about 6am. Next day 4/30 minor soreness, fatigue, soreness at injection site and ?blah? feeling with headache.  5/1/2021: woke up feeling great, other than soreness in my left arm and armpit area. By noon 5/1 most soreness gone with little to no other symptoms?
Facial nerve palsy, Bell's Palsy.  Inability to close left eye fully, unable to raise brow, unable to smile, drooling, unable to purse lips and hold air in mouth.    Treated with Prednisone and Valtrex.  Having some improvement after a week and anticipate full recovery.
Sore Throat; Body aches; Headache; This spontaneous case was reported by a consumer and describes the occurrence of OROPHARYNGEAL PAIN (Sore Throat), PAIN (Body aches) and HEADACHE (Headache) in a 76-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 007M20A) for COVID-19 vaccination.     Concomitant products included APIXABAN (ELIQUIS), ASCORBIC ACID, BETACAROTENE, CUPRIC OXIDE, TOCOPHERYL ACETATE, ZINC OXIDE (PRESERVISION), PARACETAMOL (TYLENOL), POTASSIUM CHLORIDE (KLOR-CON), TRAMADOL, CITALOPRAM, FUROSEMIDE, GABAPENTIN, LISINOPRIL and LORAZEPAM for an unknown indication.   On 28-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In 2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced OROPHARYNGEAL PAIN (Sore Throat), PAIN (Body aches) and HEADACHE (Headache). At the time of the report, OROPHARYNGEAL PAIN (Sore Throat), PAIN (Body aches) and HEADACHE (Headache) had resolved.            No treatment information was reported.
Immediately after the vaccine a large welt formed at the site of vaccination.  There also was a red rash that appeared around the site.  Patient reported she didn't feel any pain.  After about 20 minutes the swelling went down.  She reported still not feeling any pain at the site.  We observed patient for 30 minutes.  Swelling went down, skin was not hot or flushed at the site.  Patient was instructed to continue to monitor and would follow up with emergency room or primary care if she felt it was necessary.  She was not given any medications while on site.  She continued to feel fine with no trouble breathing, no dizziness, or any other complaints.
Patient developed intussusception 12 days after receiving Rotateq. Reduction required surgery. 12/29/08-records received for DOS 11/16-11/19/08-DC DX: Intussusception, status post open reduction.  Presented with intermittent severe episodes of abdominal pain. DC Summary for DOS 11/16-11/19/08-DC DX: Intussusception status post open reduction. Presented with C/O abdominal pain, lethargy.
Went to minor ER clinic for a sinus infection.  Because summer is upon us, I requested a tetanus shot since I hadn't had one for years.  I was given a shot and sent home and told not to lay on that arm for a day or so.  This was April 3, 2008.  My arm, shoulder and neck are still sore including causing headaches, unable to sleep, difficulty typing, dressing, picking anything up including sometimes even my coffee cup.
Next day:  headache and arm ache. 2nd day: large red patch around injection site; warm to touch. 4-12th days:  Beginning "hives" around neck.... gradually progressing to under arms .... then to groin area; a lot of itching; topical CALADRYL and BENADRYL tabs taken; temp relief only. 13th day: symptoms continue; have not sought medical TX yet, but thinking about it.
pt recvd vax 10SEP93 & 7NOV93 pt devel fever, URI sx & a sore throat; pt wa hospitalized & a blood culture confirmed the presence of Haemophilus influenza, type A; dx w/bacterial meningitis, hypoxia, & sepsis;
Flushed face, light dizziness and mild confusion immediately after injection.  Nearly 2 days later, I am still feeling noticable confusion, difficulty with average tasks, mild dizziness and mild hallucinations ( shadows in peripherals ), weakness and inflamed musculoskeletal response with unusually increased hunger.
I had a headache and started having a sore throat 6 hours after. By 3 in the morning, my whole body ached and I had a fever of 101.6F.
Asthma attack, inhaler, cold air outside, oral steroid. 11/13/09:  Primary Care record received for date of service 11/2/09.  Dx:  Cough variant asthma. Assessment:  Presents with congestion and drainage.  Productive at times.  The course has progressively worsened.  It is of moderate intensity with no obvious aggravating factors.  No fever.  Pt. is mouth breathing.  Has vomited once from coughing. Frequent dry, hacking cough.  SpO2 98% on room air.  Prescribed Orapred, Flovent HFA and albuterol.
after first dose, was totally whacked out and was in bed for 24 hours; Had absolutely no energy the following night; I stayed in bed for 24 hours because I was just totally exhausted; Well the first one totally wiped out so I expected that. I wasn't surprised. I was in bed for 24 hours; This is a spontaneous report from a contactable consumer (patient himself). An 80-years-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, formulation: solution for injection, lot number: FC3181, expiry date: unknown) via unspecified route of administration in left arm on 23Aug2021 (age at vaccination: 80-years) as dose 1, single for covid-19 immunisation. Medical history of patient included Diabetes, Moderate kidney disease, Cholesterol, High Blood pressure, blood pressure, and water pill from an unknown date and unknown if ongoing. Concomitant medications included hydrochlorothiazide 25 mg, daily as water pill, amlodipine besilate, 10 mg daily for high blood pressure, atenolol 100 mg for blood pressure, omeprazole 20 mg daily for unknown indication, atorvastatin calcium 40 mg, daily for cholesterol. After first dose, patient had absolutely no energy the following night, Wednesday night, and stayed in bed for 24 hours because he was just totally exhausted on 23Aug2021. No additional vaccines administered on same date of the Pfizer suspect. Prior Vaccinations (within 4 weeks) was administered. Here was no emergency room visit or physicians office visit due to the adverse events. Patient underwent lab test which included blood test for Covid antibodies, with results: has antibodies, on 30Jul2021. The outcome of the events was unknown.
Symptoms started the next morning, Severe fatigue, Flu symptoms ie: aching joints, aching muscles,  low grade fever, really bad headache, nausea,  These symptoms lasted 10 days.  On day 10  breathing was difficult.
Day 1 - Started to get red; light pinksh; head ache all over (flu like). Day 2 - Huge area of redness, 4 inches more down to the elbow.  Area was hot and swollen with one inch lump.  Now (one week later) the area is pink and achy.  Pain resolved 4 days later.  Patient took Celebrex 200mg QD for 4 days starting day 1, and reported that symptoms improved after taking dose.
3/20/2023 I did not feel great. On 3/21/23 I started feeling really tired, my sinuses were bothering me and had a cough that night. My husband told me I looked pale. I took an at home COVID test and it was positive. I took a second at home COVID test and it was also positive. I had an appointment with my doctor at 4:30. I had another COVID test that was positive. I was told I was not a candidate for Paxlovid because of my medication. I was told I had a virus strain of COVID. The doctor told me to go home and rest.
Narrative:  COVID infection following COVID vaccine series 03/27, Pfizer, dose #1 04/16, Pfizer, dose #2 07/09 COVID swab, result: not detected 12/22 COVID swab, result: detected 12/22 pt cc: cold symptoms exposure: unknown 2/22 pt admit ED cc: cold symptoms dx: COVID 19 LOS: 1 day 12/22 SARS-COV-2 Variant Sequencing: pending
fever up to 105 x 1/2 hrs stayed 104 x 8 hrs; crying unconsolably, chills, shaking; no diarrhea; no vomiting; no sz; no LOC; tired; inject site sl pink instructed mom to consult MD for next DTP;
Pain in arm got worse and traveled to shoulder and neck and down arm to elbow 6 days later.
Vaccine went into 2-8 Celsius thaw state on or about 20-Dec-2021 and administered on 12-Feb-2022; Covid-19 vaccine that were given beyond the 30 day use by date; This spontaneous case was reported by an emergency medical technician and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Covid-19 vaccine that were given beyond the 30 day use by date) and PRODUCT STORAGE ERROR (Vaccine went into 2-8 Celsius thaw state on or about 20-Dec-2021 and administered on 12-Feb-2022) in a 30-year-old female patient who received mRNA-1273 (Spikevax) (batch no. 066H21A) for COVID-19 vaccination.     It was reported Acute illness at the time of vaccination and up to one month before and Chronic or long-standing health conditions were unknown.     On 12-Feb-2022 at 12:50 PM, the patient received first dose of mRNA-1273 (Spikevax) (unknown route) .5 milliliter. On 12-Feb-2022 at 12:50 PM, the patient experienced EXPIRED PRODUCT ADMINISTERED (Covid-19 vaccine that were given beyond the 30 day use by date). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Vaccine went into 2-8 Celsius thaw state on or about 20-Dec-2021 and administered on 12-Feb-2022). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Covid-19 vaccine that were given beyond the 30 day use by date) and PRODUCT STORAGE ERROR (Vaccine went into 2-8 Celsius thaw state on or about 20-Dec-2021 and administered on 12-Feb-2022) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter did not provide any causality assessments.   Prescriptions, over the counter medications, dietary supplements or herbal remedies being taken at time of vaccination and/or at the time of adverse event were unknown. Other vaccine given on the same day as that of Moderna vaccine was unknown. Other vaccines received within one month prior to any dose of Moderna COVID-19 vaccine was unknown.  Patient was administered vaccine past its 30 days expiry date vaccine went into 2 to 8 Celsius thaw state on or about to 20-Dec-2021, this vaccine was administered until its manufacturing (Mfg) expiration date of 04-Apr-2022.   No treatment medication information provided.
Patient was getting up to leave and became dizzy and short of breath and states passed out.  States was out for less than 1 minute.  Per bystanders patient talking during episode but patient states everything was hazy.  PStates has history of similar episodes seem to be associated with possible painful stimuli.  Patient states feels back to normal when transferred to ED.
5 days after Moderna vaccine, developed severe abd pain, mid epigastrium. No Nausea or vomiting. No fever.  Mild diarrhea. after 48 hrs with no improvement went to ED
Inflammatory response; This spontaneous case was reported by a consumer and describes the occurrence of INFLAMMATION (Inflammatory response) in a 22-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Not available (could be Pfizer's)) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced INFLAMMATION (Inflammatory response). At the time of the report, INFLAMMATION (Inflammatory response) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No Concomitant medications were provided  No treatment medications were provided.
Patient was given Dtap instead of Tdap.  Dose does not need to be repeated based on guidance. No adverse reaction reported.
This spontaneous report was received from a medical assistant and refers to an unknown number of patients of unknown age and gender. No information on the patients' concomitant medications, pertinent medical history, drug reactions or allergies was reported. On unknown dates, the patients were vaccinated with improperly stored doses of GARDASIL 9, lot # M036059 with expiry date on 03-JUN-2019, lot # M044717 with expiry date on 19-JUL-2019, lot # N000326 with expiry date on 14-OCT-2019, and lot # N013276 with expiry date on 21-JAN-2020 (dose and route of administration were not reported). There were no adverse effects reported. Administered doses of vaccines experienced the temperature excursion of 35.2 degrees Fahrenheit for 15 days. Data logger was involved in recording the excursion details. There were no previous excursions reported. This is one of several reports received from the same reporter. Lot number N013276 has been verified to be a valid lot number for GARDASIL 9. Sender's Comments: US-009507513-1709USA004696: US-009507513-1709USA007336.
patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion); patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion); This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) in a 70-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) and POOR QUALITY PRODUCT ADMINISTERED (patients have been administered doses while the temperature excursion assessment was ongoing (possible temperature excursion)) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication was reported. The reporter was an internal medicine manager. It was reported that, there had been no power outages that would have impacted the Moderna vaccine. However, the healthcare professional reiterates that because her facility was unable to download the digital data logger, they would need to treat this issue as a temperature excursion. The data logger was unable to download for the months of Dec-2021, Jan-2022, and Feb-2022. They were filling out a temperature excursion assessment with the State at this time. It was reported that, no adverse reactions were reported by the patient. The reporter mentioned that the patient had been administered dose while the temperature excursion assessment was ongoing. The reporter also reported that, no adverse reactions were reported by the patient. No treatment medication was reported.
12 hrs post vax. Awoke vomiting, diarrhea, spinning or dizzy. After 3 months, pt is still experiencing problems. Saw otolaryngologist.
No adverse effect; Improperly stored PROQUAD; This spontaneous report was received from a medical assistant referring to a patient of unspecified age and gender.    The patient's medical history and concurrent conditions were unknown.  On 31-MAY-2019, the patient was vaccinated with one dose of improperly stored measles, mumps, rubella and varicella (oka-merck) virus vaccine live(PROQUAD) (lot # S002497 Exp.date: 23-JUL-2020) of dose 1.5 milliliter through subcutaneous route for prophylaxis (product storage error). The patient's concomitant medication included sterile diluent.  The vaccine was exposed to a temperature of -4.3 C for a time frame of 3 hours and 21 minutes. There was no previous temperature excursion. No adverse events was reported.
Presented to ED from NH where he was recovering from COVID-19 (dx at recent hospital stay) w c/o SOB & decreased O2 saturation; admitted for peristent COVID-19 pna; tx w/abx, O2, steroids, zinc; dc'd to LTAC d/t continuing need for high O2.
Around 2 hours after receiving the vaccine I became tired the next day after I woke up I was very dizzy for about 3 hours in the morning around 5:00 that evening on the 21st everything seems to be cleared up and gone I've been fine ever since
12-36 hr p/vax stiffness, arm pain; 36-48 hr p/vax low fever, swelling of glands in chest under the jaw-MD suspect strep throat ATBs started; throat culture neg strep throat;
Approximately one week later I started to have some cold symptoms and a cough, by that Saturday I had spent the night a wake wheezing and coughing, I went to Patient First, my fever 102.1, They did a rapid covid test was negative, I had a chest x-ray, blood work and my white blood cells had indicated that I had a severe infection.  They an inhaler and a medicine some kind of Terle cough medicine. two days later I saw my primary and my lungs were clear by that time.  I'm feeling better today still taking my meds and inhaler.
This spontaneous report was received from a nurse and refers to an unspecified patient of unknown age and gender. There was no information regarding the patient's pertinent medical history, drug reactions, allergies or concomitant therapies provided. On 20-FEB-2017, the patient was vaccinated with improperly stored dose of VARIVAX lot # M005974, expiration date 02-FEB-2018 (site, dose and route of administration were not reported). The reason of the call was temperature alarm received via Digital Data Logger. It was reported that the vaccine were exposed to temperature of -14.4 Celsius degrees for 54 minutes before administration. No previous temperature excursion was reported. No adverse effects were reported. This is one of several reports received from the same reporter. Additional information is not expected because all information was obtained. Sender's Comments: US-009507513-1611USA004113.
Havrix given after temperature excursion; This case was reported by a other health professional via call center representative and described the occurrence of incorrect storage of drug in a 1-year-old female patient who received HAV (Havrix) (batch number F7X23, expiry date 25th May 2023) for prophylaxis.   Co-suspect products included hepatitis A vaccine pre-filled syringe device (Havrix Pre-Filled Syringe Device) injection syringe for prophylaxis.   On 23rd November 2022, the patient received Havrix and Havrix Pre-Filled Syringe Device. On an unknown date, unknown after receiving Havrix and Havrix Pre-Filled Syringe Device, the patient experienced incorrect storage of drug. On an unknown date, the outcome of the incorrect storage of drug was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 16-FEB-2023 Reporter's Comment: The reporter called to inform that a dose of Havrix that had been in a below temperature excursion and was not considered stable was administered to a patient. The reporter stated that below temperature excursion had happened in October. The Vaccine Administration Facility was the same as primary reporter. The reporter consented to follow up.  Additional Supportive Information: The reporter called to inform that a dose of Havrix that had been in a below temperature excursion and was not considered stable was administered to a patient, which led to incorrect storage of drug. This was 1 of 5 cases, reported by the same reporter.; Sender's Comments:  US-GSK-US2023026693:Same reporter US-GSK-US2023026692:Same reporter US-GSK-US2023026695:Same reporter US-GSK-US2023026696:Same reporter US-GSK-US2023026698:Same reporter
I felt so exhausted, I was almost nonfunctioning, I practically fell into bed. The next morning, I took a home COVID-19 test that came back positive. I called to have a telehealth visit to let my doctor know that I tested positive for CVOID-19. I was prescribed the antiviral Paxlovid that I was able to start that day. This is the second time I have had COVID-19, it seemed to hang on longer this time. It took a week and a half before I really felt like I wanted to get out of bed. I feel like I have long haul COVID-19 symptoms, my memory is foggy, I am more fatigued than I ever was before.
100.9 fever; chills; muscle aches; extreme lethargy; swollen lymph node; This is a spontaneous report from a contactable consumer (patient). A 41-years-old female non-pregnant patient received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Solution for injection, Batch/Lot Number: EN5318), dose 1 via an unspecified route of administration, administered in Arm Left on 12Feb2021 at 14:00 (at the age of 41-years-old) as a dose 1, single for covid-19 immunisation. The patient medical history was not reported. Concomitant medications in two weeks included metoprolol (METOPROLOL), trazodone (TRAZODONE), norethindrone [norethisterone] (NORETHINDRONE [NORETHISTERONE]), amlodipine (AMLODIPINE) all were taken for an unspecified indication, start and stop date were not reported. Other vaccine received in four weeks was none. Patient did not have covid prior vaccination and was not tested for covid post vaccination. On 06Mar2021 06:00, the patient experienced 100.9 fever, chills, muscle aches, extreme lethargy and swollen lymph node under armpit on same side of injection. The patient received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Solution for injection, Batch/Lot Number: EL9266), dose 2 via an unspecified route of administration, administered in Arm Left on 05Mar2021 as a DOSE 2, SINGLE for covid-19 immunisation. Patient did not receive any treatment for the event. The patient underwent lab tests and procedures which included pyrexia that was 100.9 on 06Mar2021. Outcome of all the events were recovered in 2021.  No follow-up attempts are possible. No further information is expected.